N-3 fatty acids and diabetes

Biomedicine and Pharmacotherapy

Volumn 56, Issue 8, 2002, Pages 397-406

  Sirtori, C R ^a   Galli, C ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Diabetes; Hypertriglyceridemia; N 3 fatty acids

Indexed keywords

DOCOSAHEXAENOIC ACID; FATTY ACID ESTER; FISH OIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

CLINICAL TRIAL; DIABETES MELLITUS; DIET SUPPLEMENTATION; DISEASE COURSE; DISEASE PREDISPOSITION; FISH; FOOD INTAKE; HEART RATE VARIABILITY; HUMAN; HYPERCHOLESTEROLEMIA; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; LONG TERM CARE; PATHOGENESIS; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; CARDIOVASCULAR DISEASE; DIET THERAPY; DRUG EFFECT; GLUCOSE INTOLERANCE; HEART RATE; METABOLISM; TIME;

ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; DIABETES COMPLICATIONS; DIABETES MELLITUS; FATTY ACIDS, OMEGA-3; FISH OILS; GLUCOSE INTOLERANCE; HEART RATE; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; TIME FACTORS; TRIGLYCERIDES;

EID: 0036776023     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(02)00255-X     Document Type: Article

References (63)

1. Angerer P., von Schacky C. N-3 polyunsaturated fatty acids and the cardiovascular system. Curr Opin Lipidol. 11:2000;57-63.
2. Hooper L., Summerbell C.D., Higgins J.P.T., Thompson R.J., Capps N.E., Smith G.D., Riemersma R.A., Ebrahim S. Dietary fat intake and prevention of cardiovascular disease: systematic review. BMJ. 322:2001;757-763.
3. Harris W.S. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr. 65:1997;1645S-1654S.
4. Fischer S., Weber P.C., Dyerberg J. The prostacyclin/thromboxane balance is favourably shifted in Greenland Eskimos. Prostaglandins. 32:1986;235-241.
5. Mori T.A., Watts G.F., Burke V., Hilme E., Puddey I.B., Beilin L.J. Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. Circulation. 102:2000;1264-1269.
6. Kang J.X., Leaf A. Prevention of fatal cardiac arrhythmias by polyunsaturated fatty acids. Am J Clin Nutr. 71:2000;202S-207S.
7. + channel. Proc Natl Acad Sci. 95:1998;2680-2685.
8. Brenner R. Endocrine control of fatty acid desaturation. Biochem Soc Trans. 18:1990;773-775.
9. McLennan P.L., Raederstorff D. Diabetes puts myocardial n-3 fatty acid status at risk in the absence of supplementation in the rat. Lipids. 34:1999;S91-92.
10. Dyck D.J., Steinberg G., Bonen A. Insulin increases FA uptake and esterification but reduces lipid utilization in isolated contracting muscle. Am J Physiol. 281:2001;E600-607.
11. Marangoni F., Mosconi C., Galella G., Galli C. Increments of dietary linoleate raise liver arachidonate, but markedly reduce heart n-6 and n-3 fatty acids in the rat. Lipids. 27:1992;624-628.
12. Glauber H., Wallace P., Griver K., Brechtel G. Adverse effects of ω-3 fatty acids in non-insulin-dependent diabetes mellitus. Ann Intern M. 108:1988;663-668.
13. Stacpoole P.W., Alig J., Ammon L., Crockett S.E. Dose-response effects of dietary marine oil on carbohydrate and lipid metabolism in normal subjects and patients with hypertriglyceridemia. Metabolism. 38:1989;946-956.
14. Borkman M., Chisholm D.J., Furler S.M., Storlien L.H., Kraegen E.W., Simon L.A., Chesterman C.N. Effects of fish oil supplementation on glucose and lipid metabolism in NIDDM. Diabetes. 38:1989;1314-1319.
15. Schectman G., Kaul S., Kissebah A.H. Effects of fish oil concentrate on lipoprotein composition in NIDDM. Diabetes. 37:1988;1567-1573.
16. Annuzzi G., Rivellese A., Capaldo B., Di Marino L., Iovine C., Marotta G., Riccardi G. A controlled study on the effects of n-3 fatty acids on lipid and glucose metabolism in non-insulin-dependent diabetic patients. Atherosclerosis. 87:1991;65-73.
17. Fashing P., Ratheiser K., Waldhausl W., Rohac M., Osterrode W., Nowotny P., Vierphapper H. Metabolic effects of fish-oil in patients with impaired glucose tolerance. Diabetes. 40:1991;583-589.
18. Storlien L.H., Kraegen E.W., Chisholm D.J., Ford G.L., Bruce D.G., Pascoe W.S. Fish oil prevents insulin resistance induced by high-fat feeding in rats. Science. 237:1987;885-888.
19. Howard W.J. Is it time for a clinical trial of dietary fish oil supplementation in individuals with NIDDM? Ann NY Acad Sci. 683:1993;341-342.
20. Franceschini G., Calabresi L., Maderna P., Galli C., Gianfranceschi G. Sirtori CR. ω-3 fatty acids selectively raise high-density lipoprotein 2 levels in healthy volunteers. Metabolism. 40:1991;1283-1286.
21. Sirtori C.E., Galli C., Franceschini G. Fraudulent (and non fraudulent) fatty acids for human health. Eur J Clin Invest. 23:1993;686-689.
22. Konard R.J., Stoller J.Z., Gao J.Z., Wolf B.A. Eicosapentaenoic acid (C20:5) augments glucose-induced insulin secretion from beta-TC3 insulinoma cells. Pancreas. 13:1996;253-258.
23. Chin J.P.F., Gust A.P., Nestel P.J., et al. Fish oils dose-dependently inhibit vasoconstriction of forearm resistance vessels in humans. Hypertension. 21:1993;22-28.
24. Singh R.B., Niaz M.A., Sarma J.P., et al. Randomized, double blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian Experiment of Infarct Survival-4. Cardiovasc Drug Ther. 11:1997;485-491.
25. Zambon S., Friday K.E., Childs M.T., Fujimoto W.Y., Bierman E.L., Ensinck J.W. Effect of glyburide and ω-3 fatty acid dietary supplements on glucose and lipid metabolism inpatients with non-insulin-dependent diabetes mellitus. Am J Clin Nutr. 56:1992;447-454.
26. Friday K.E., Childs M.T., Tsunehara C.H., Fujimoto W.Y., Bierman E.L., Ensinck J.W. Omega-3 fatty acid supplementation raises plasma glucose while lowering triglyceride levels in type II diabetes. Diabetes Care. 12:1989;276-281.
27. Ezaki O., Tsuji E., Momomura K., Kasuga M., Itakura H. Effects of fish and safflower oil feeding on subcellular glucose transporter distributions in rat adipocytes. Am J Physiol. 263:1992;E94-E101.
28. Toft I., Bonaa K.H., Ingebretsen O.C. Nordoy A, Jensenn T. Effects of n-3 polyunsaturated fatty acids on glucose homeostasis and blood pressure in essential hypertension. Ann Intern M. 123:1995;911-918.
29. Reaven G.M. Role of insulin resistance in human disease. Diabetes. 37:1988;1596-1607.
30. Sirtori C.R., Paoletti R., Mancini M., Crepaldi G., Manzato E., Rivellese A., Pamparana F., Stragliotto E., on behalf of the Italian Fish Oil Multicenter Study . N-3 fatty acids do not lead to an increased diabetic risk in patients with hyperlipidemia and abnormal glucose tolerance. Am J Clin Nutr. 65:1997;1874-1881.
31. Sirtori C.R., Crepaldi G., Manzato E., Mancini M., Rivellese A., Paoletti R., Pazzucconi F., Pamparana F., Stragliotto E. One-year of treatment with ethyl esters of n-3 fatty acids in patients with hypertriglyceridemia and glucose intolerance. Reduced triglyceridemia, total cholesterol and increased HDL-C without glycemic alterations. Atherosclerosis. 137:1998;419-427.
32. Austin M.A., Brunzell J.D., Fitch W.L., Krauss R.M. Inheritance of low density lipoprotein subclass patterns in familial combined hyperlipidemia. Arteriosclerosis. 10:1990;520-530.
33. Cortner J.A., Coates P.M., Bennet M.J., Cryer D.R., Ngoc-Anh L. Familial combined hyperlipidaemia: use of stable isotopes to demonstrate overproduction of very low-density lipoprotein apolipoprotein B by the liver. J Inherit Metab Dis. 14:1991;915-922.
34. Venkatesan S., Cullen P., Pacy P.J., Halliday D., Scott J. Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arterioscler Thromb. 13:1993;1110-1118.
35. Austin M.A., King M.C., Vranizan K.M., Krauss R.M. Atherogenic lipoprotein phenotype: a proposed genetic marker of coronary heart disease risk. Circulation. 82:1990;495-506.
36. Austin M.A., Breslow J.L., Hennekens C.H., Buring G.E., Willet W.C., Krauss R.M. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 13:1988;1917-1921.
37. Rajman I., Kendall M.J., Cramb R., Holder R.L., Salih M., Gammage M.D. Investigation of low density lipoprotein subfractions as a coronary risk factor in normotriglyceridaemic men. Atherosclerosis. 125:1996;231-242.
38. Goldstein J.L., Schrott H.G., Hazzard W.R., Bierman E.L., Motulsky A.G. Hyperlipidemia in coronary heart disease. II. Genetic analysis in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 52:1973;1544-1568.
39. Franceschini G., Cassinotti M., Vecchio G., Gianfranceschi G., Pazzucconi F., Murakami T., Sirtori M., D'Acquarica A.L., Sirtori C.R. Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern. Arterioscler Thromb. 14:1994;1569-1575.
40. Bredie S.J., de Bruin T.W., Demacker P.N., Kastelein J.J., Stalenhoef A.F. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. Am J Cardiol. 75:1995;348-353.
41. Aguilar-Salinas C.A., Hugh P., Barrett R., Pulai J., Zhu X.L., Schonfeld G. A familial combined hyperlipidemic kindred with impaired apolipoprotein B catabolism. Kinetics of apolipoprotein B during placebo and pravastatin therapy. Arterioscler Thromb Vasc Biol. 17:1997;72-82.
42. Hokanson J.E., Austin M.A., Zambon A., Brunzell J.D. Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia. Arterioscler Thromb. 13:1993;427-434.
43. Inagaki M., Harris W.S. Changes in lipoprotein composition in hypertriglyceridemic patients taking cholesterol-free fish oil supplements. Atherosclerosis. 82:1990;237-246.
44. Nenseter M.S., Rustan A.C., Lund-Katz S., Soyland E., Maelandsmo G., Phillips M.C., Drevon C.A. Effect of dietary supplementation with n-3 polyunsaturated fatty acids on physical properties and metabolism of low density lipoprotein in humans. Arterioscler Thromb. 12:1992;369-379.
45. Contacos C., Barter P.J., Sullivan D.R. Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia. Arterioscler Thromb. 13:1993;1755-1762.
46. Suzukawa M., Abbey M., Howe P.R., Nestel P.J. Effects of fish oil fatty acids on low density lipoprotein size, oxidizability, and uptake by macrophages. J Lipid Res. 36:1995;473-484.
47. Failor R.A., Childs M.T., Bierman E.L. The effects of omega-3 and omega-6 fatty acid-enriched diets on plasma lipoproteins and apoproteins in familial combined hyperlipidemia. Metabolism. 37:1988;1021-1028.
48. Harris W.S., Ginsberg H.N., Arunakul A., Shachter N.S., Windsor S.L., Adams M., Berglund L., Osmundsen K. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk. 4:1997;385-391.
49. Calabresi L., Donati D., Pazzucconi F., Sirtori C.R., Franceschini G. Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. Atherosclerosis. 148:2000;387-396.
50. Griffin B.A., Freeman D.J., Tait G.W., Thomson J., Caslake M.J., Packard C.J., Shepherd J. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis. 106:1994;241-253.
51. Malliani A., Pagani M., Lombardi F., Cerutti S. Cardiovascular neural regulation explored in the frequency domain. Circulation. 84:1991;482-492.
52. Multicenter Post-Infarction Research Group, Kleiger RE, Miller JP, Bigger JT, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987;59:256-262.
53. Lialo D., Sloan R.P., Cascio W.E., Folsom A.R., Liese A.D., Evans G.W., Cai J., Sharrett A.R. Multiple metabolic syndrome is associated with lower heart rate variability. Diabetes Care. 21:1998;2116-2122.
54. Harper C.R., Jacobson T.A. The fats of life. The role of omega-3 fatty acids in the prevention of coronary heart disease. Arch Intern M. 161:2001;2185-2192.
55. Christensen J.H., Gustenhoff P., Korup E., Aaroe J., Toft E., Moller J., Rasmussen K., Dyerberg J., Schmidt E.B. Effects of fish oil on heart rate variability in survivors of myocardial infarction: a double blind randomized controlled trial. BMJ. 312:1996;677-678.
56. Christensen J.H., Skou H.A., Fog L., Hansen V., Vesterlund T., Dyerberg J., Toft E., Schmidt E.B. Marine n-3 fatty acids, wine intake, and heart rate variability in patients referred for coronary angiography. Circulation. 103:2001;651-657.
57. Villa B., Calabresi L., Chiesa G., Risè P., Galli C., Sirtori C.R. Omega-3 fatty acid ethyl esters increase heart rate variability in patients with coronary disease. Pharmacol Res. 45:2002;475-478.
58. Furlan R., Guzzetti S., Crivellaro W., Dassi S., Tinelli M., Baselli G., Cerutti S., Lombardi F., Pagani M., Malliani A. Continuous 24 hours assessment of the neural regulation of systemic arterial pressure and RR variabilities in ambulant subjects. Circulation. 81:1990;537-547.
59. Huikuri H.V., Jokinen V., Syvanne M., Nieminen M.S., Airaksinen K.E., Ikaheimo M.J., Koistinen J.M., Kauma H., Kesaniemi A.Y., Majahalme S., Niemela K.O., Frick M.H. Heart rate variability and progression of coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 19:1999;1979-1985.
60. La Rovere M.T., Bigger J.T., Marcus F.I., Mortara A., Schwartz P.J. Baroflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet. 351:1998;478-484.
61. Anonymous. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 354:1999;447-455.
62. Dewailly E., Blanchet C., Gingras S., Lemieux S., Sauvé L., Bergeron J., Holub B.J. Relation between n-3 fatty acid status and cardiovascular disease risk factors among Quebecers. Am J Clin Nutr. 74:2001;603-611.
63. Ebbesson S.O., Kennish J., Ebbeson L., Go O., Yeh J. Diabetes is related to fatty acid imbalance in Eskimos. Int J Circumpolar Health. 58:1999;108-119.